Superheroes in autoimmune warfare: Biologic therapies in current SA practice

dc.contributor.authorTarr, G
dc.contributor.authorHodkinson, B
dc.contributor.authorReuter, H
dc.date.accessioned2021-10-08T07:20:29Z
dc.date.available2021-10-08T07:20:29Z
dc.date.issued2014
dc.description.abstractBiologic drugs targeting immune cells or cytokines underlying systemic inflammation have dramatically improved outcomes in patients with rheumatological and autoimmune diseases. Nine biologic drugs are currently available in South Africa (SA) - all showing good efficacy and safety profiles. Their high cost and potential adverse events preclude them from being used as first-line agents. They are therefore indicated for severe disease refractory to standard therapies, and their use must be initiated by a specialist. The most important adverse effect of this class of drugs is infection and, in SA, tuberculosis is of particular concern. As new targets in the immune system are identified, new biologics will be developed. The current challenges are to optimise standard care for all patients with autoimmune diseases, and to offer the appropriate biologic to patients with refractory disease.
dc.identifier.apacitationTarr, G., Hodkinson, B., & Reuter, H. (2014). Superheroes in autoimmune warfare: Biologic therapies in current SA practice. <i>South African Medical Journal</i>, 104(11), 787 - 177. http://hdl.handle.net/11427/34932en_ZA
dc.identifier.chicagocitationTarr, G, B Hodkinson, and H Reuter "Superheroes in autoimmune warfare: Biologic therapies in current SA practice." <i>South African Medical Journal</i> 104, 11. (2014): 787 - 177. http://hdl.handle.net/11427/34932en_ZA
dc.identifier.citationTarr, G., Hodkinson, B. & Reuter, H. 2014. Superheroes in autoimmune warfare: Biologic therapies in current SA practice. <i>South African Medical Journal.</i> 104(11):787 - 177. http://hdl.handle.net/11427/34932en_ZA
dc.identifier.issn0038-2469
dc.identifier.ris TY - Journal Article AU - Tarr, G AU - Hodkinson, B AU - Reuter, H AB - Biologic drugs targeting immune cells or cytokines underlying systemic inflammation have dramatically improved outcomes in patients with rheumatological and autoimmune diseases. Nine biologic drugs are currently available in South Africa (SA) - all showing good efficacy and safety profiles. Their high cost and potential adverse events preclude them from being used as first-line agents. They are therefore indicated for severe disease refractory to standard therapies, and their use must be initiated by a specialist. The most important adverse effect of this class of drugs is infection and, in SA, tuberculosis is of particular concern. As new targets in the immune system are identified, new biologics will be developed. The current challenges are to optimise standard care for all patients with autoimmune diseases, and to offer the appropriate biologic to patients with refractory disease. DA - 2014 DB - OpenUCT DP - University of Cape Town IS - 11 J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 2014 SM - 0038-2469 T1 - Superheroes in autoimmune warfare: Biologic therapies in current SA practice TI - Superheroes in autoimmune warfare: Biologic therapies in current SA practice UR - http://hdl.handle.net/11427/34932 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34932
dc.identifier.vancouvercitationTarr G, Hodkinson B, Reuter H. Superheroes in autoimmune warfare: Biologic therapies in current SA practice. South African Medical Journal. 2014;104(11):787 - 177. http://hdl.handle.net/11427/34932.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Medicine
dc.publisher.facultyFaculty of Health Sciences
dc.sourceSouth African Medical Journal
dc.source.journalissue11
dc.source.journalvolume104
dc.source.pagination787 - 177
dc.source.urihttps://dx.doi.org/10.7196/SAMJ.8947
dc.subject.otherAntibodies, Monoclonal, Humanized
dc.subject.otherAntirheumatic Agents
dc.subject.otherAutoimmune Diseases
dc.subject.otherHumans
dc.subject.otherImmunosuppressive Agents
dc.subject.otherReceptors, Interleukin-6
dc.subject.otherSouth Africa
dc.subject.otherTumor Necrosis Factor-alpha
dc.subject.otherAntibodies, Monoclonal, Humanized
dc.subject.otherAntirheumatic Agents
dc.subject.otherIL6R protein, human
dc.subject.otherImmunosuppressive Agents
dc.subject.otherReceptors, Interleukin-6
dc.titleSuperheroes in autoimmune warfare: Biologic therapies in current SA practice
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
TarrG_Superheroes_in_2014.pdf
Size:
607.85 KB
Format:
Adobe Portable Document Format
Description:
Collections